期刊文献+

肿瘤坏死因子相关凋亡诱导配体对非小细胞肺癌细胞凋亡诱导的实验研究 被引量:1

Induction of apoptosis with TRAIL in non-small lung cancer
下载PDF
导出
摘要 目的研究肿瘤坏死因子相关凋亡诱导配体(TRAIL)对非小细胞肺癌肿瘤细胞体外诱导凋亡作用,探讨TRAIL治疗肺癌的可行性。方法 (1)单用组:单用不同浓度的TRAIL溶液处理A549并与白血病Jurkat细胞对照;(2)联合组:相同浓度的TRAIL联合不同化疗药物处理A549并与对应的单纯化疗药物对照,用MTT法及流式细胞仪检测处理前后A549细胞的凋亡发生率并比较。结果 TRAIL溶液能使部分体外非小细胞肺癌发生凋亡,TRAIL溶液浓度与细胞凋亡率在一定程度上呈正相关;联合化疗药物后的TRAIL溶液对肿瘤细胞杀灭能力显著强于单用化疗药物组,差异有统计学意义(P<0.05)。结论 TRAIL可诱导小部分非小细胞肺癌细胞体外凋亡,其凋亡作用在一定范围内与TRAIL浓度呈正相关,TRAIL联合常用化疗药物有协同促进肿瘤细胞凋亡的作用。 Objective To investigate the effect of TNF-related apoptosis inducing ligand(TRAIL) in inducing apoptosis in non-small cell lung cancer, and to explore the feasibility of TRAIL in treatment of lung cancer. Methods The single group: the cells in the two group with solutions of different concentrations of TRAIL A549 and the feasibility of TRAIL treatment between the NSCLC group and the Jurkat leukemia cell group was compared. The combination group: same concentrations of TRAIL combined with different chemotherapy treatment A549 and the corresponding chemotherapy drugs were compared, apoptosis was detected by MTT assay before and after treatment of A549 cells the incidence of parallel statistical comparison. Results TRAIL was able to make part of the non-small cell lung cancer apoptosis in vitro, TRAIL apoptosis rate and concentration had a positive correlation to some extent; TRAIL solution after combination chemotherapy drugs kill tumor cells was significantly stronger ability to eliminate drugs in the chemotherapy alone, the difference was statistically significant(P<0.05). Conclusion TRAIL can induce lung cancer cells in vitro,small portion of non-small cell apoptosis of apoptosis within a certain range of concentrations are positively related with TRAIL, TRAIL combined chemotherapy drugs have synergistic apoptosis of tumor cells.
作者 王建新
出处 《中国现代医生》 2015年第14期1-3,共3页 China Modern Doctor
关键词 非小细胞肺癌 肿瘤坏死因子相关凋亡诱导配体 凋亡 Non-small cell lung cancer Tumor necrosis factor-related apoptosis inducing ligand Apoptosis
  • 相关文献

参考文献12

  • 1Anita C.Bellail,Margaret C. L.Tse,Jin H.Song,SurasakPhuphanich,Jeffrey J.Olson,Shi YongSun,ChunhaiHao.DR5‐mediated DISC controls caspase‐8 cleavage and initiation of apoptosis in human glioblastomas[J]. Journal of Cellular and Molecular Medicine . 2010 (6a)
  • 2Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial[J]. Lancet Oncology . 2012 (3)
  • 3F. Yang,P. Shi,X. Xi,S. Yi,H. Li,Q. Sun,M. Sun.Recombinant adenoviruses expressing TRAIL demonstrate antitumor effects on non-small cell lung cancer (NSCLC)[J]. Medical Oncology . 2003 (2)
  • 4Lee S H,Shin M S,Kim H S,Lee H K,Park W S,Kim S Y,Lee J H,Han S Y,Park J Y,Oh R R,Jang J J,Han J Y,Lee J Y,Yoo N J.Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. Cancer Research . 1999
  • 5Spierings DC,de Vries EG,Vellenga E,et al.Tissue distribution of the death ligand TRAIL and its receptors. Journal of Histochemistry and Cytochemistry . 2004
  • 6Bellail Anita C,Qi Ling,Mulligan Patrick,Chhabra Vaninder,Hao Chunhai.TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Reviews on recent clinical trials . 2009
  • 7Jeffrey Wiezorek,Pamela Holland,Jonathan Graves.Death Receptor Agonists as a Targeted Therapy for Cancer. Clinical Cancer Research . 2010
  • 8Bunn P A,Vokes E E,Langer C J,Schiller J H.An update on North American randomized studies in non-small cell lung cancer. Seminars in Oncology . 1998
  • 9Kim C Y,Jeong M,Mushiake H,et al.Cancer gene therapy using a novel secretable trimeric TRAIL. Gene Therapy . 2005
  • 10王绩英,王昌明,曾锦荣,莫碧文,蒋明.肿瘤坏死因子相关凋亡诱导配体对肺癌细胞的杀伤作用研究[J].华中医学杂志,2005,29(4):259-260. 被引量:5

二级参考文献32

  • 1C. Gridelli, et al. International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by second-line E in advanced non-small cell lung cancer (aNSCLC) [J]. ASCO, 2010, Abstract 7508.
  • 2Y. Bang, et al. Clinical activity of the oral ALK inhibitor PF- 02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC)[J]. ASCO, 2010 Abstract 3.
  • 3M. J. Boyer et al. Efficacy and safety of PF299804 versus erlotinib (E) : A global, randomized phase Ⅱ trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT)[J]. ASCO, 2010, Abstract 7523.
  • 4C. Yang, et al. A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2).
  • 5Tony Mok, et al. Clinical outcomes of patients with epidermai growth factor receptor (EGFR) mutations (Mut) in IPASS 2009 WCLC Abstract B9.5.
  • 6Jin S. Lee et al. First-SIGNAL To examine the role of Gefitinib as first-line therapy in never-smoker lung cancer patients with adenocarcinoma as compared with standard chemotherapy Gemcitabine plus Cisplatin 2009 WCLC Abstract PRS. 4.
  • 7Sandler A, Gray R, Perry MC, et al. Paclitaxel carboplatin a- lone or with bevacizumab for non-smallcell lung cancer[J]. N Engl J Med,2006, 355:2542-2550.
  • 8Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gcmcitabine and cisplatin in advanced non-small-cell lung cancer: A phase Ⅲ trial-INTACT 1[J]. J Clin Oncol, 22: 777-784.
  • 9Herbst RS, Prager D, Hermann R, et al. TRIBUTE: A phase Ⅲ trial of erlotinib hydroehloride (OSI-774) combined with earboplatin and paelitaxel chemotherapy in advanced non-small-cell lung eaneer[J]. J Clin Oncol,2005, 23:5892-5899.
  • 10Herbst RS, Giaeeone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer, A phase Ⅲ trial-INTACT 2[J]. J Clin Oncol, 2004, 22:785-794.

共引文献39

同被引文献13

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部